Cambridge based bit.bio announced a USD 25 million Series D on 4 November 2026 from existing investor M and G Investments and biotechnology entrepreneur Jonathan Milner. No lead was stated. The company uses its cell programming technology to manufacture defined human cell models for research and drug development. Researchers use the cells to study disease biology, test compounds and build more consistent experiments. bit.bio said demand for its products had reached record levels. The financing will expand product development, manufacturing and commercial reach as the company adds cell types and works with pharmaceutical and biotechnology customers.
bit.bio raises USD 25m Series D
Fresh capital supports programmable human cell models

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


